The emergence of coronavirus disease 2019 (COVID-19), which caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has put unprecedented challenges on the public health \[[@CR1], [@CR2]\]. It is well- known that most of the infected patients presented with fever or respiratory manifestations, while a portion of patients presented with gastrointestinal (GI) symptoms \[[@CR2]\]. In early published study from the USA, SARS-CoV-2 viral RNA has been present in the feces of the illness \[[@CR3]\]. However, part of COVID-19 patients present GI symptoms at the onset of diseases may be overlooked by clinicians \[[@CR4]\].

Our experience was conducted in Ningbo First Hospital, Jingzhou Central Hospital, and Hubei Provincial Hospital of Integrated Chinese & Western Medicine. One hundred fifty-seven patients we treated were diagnosed as COVID-19 according to the World Health Organization interim guidance \[[@CR5]\]. Nasopharyngeal swabs and chest computed tomography were collected from all patients. Demographic data, symptoms, laboratory values, comorbidities, and clinical outcomes were collected from the electronic medical records.

Of 157 patients with COVID-19, 63 (40.1%) presented with 1 or more GI symptoms (anorexia, nausea, or diarrhea). The mean age of 157 patients was 49.3 years (standard deviation, SD, 14.5), and 74 (47.1%) were male.

Of the 63 patients, 21 (33.3%) had nausea, 47 (74.6%) had anorexia, and 25 (39.7%) had diarrhea. The mean age of those patients was 51.9 years (SD, 14.9). Twenty-four (38.1%) were male, and 24 (38.1%) had chronic diseases. The most common symptoms were cough, fatigue, fever, and muscle soreness. Neither the median white blood cell nor lymphocyte counts were different between patients with and without GI symptoms (Table [1](#Tab1){ref-type="table"}). Table 1Demographics and clinical features of coronavirus disease 2019Total (***n*** = 157)GI symptoms(***n*** = 63)Without GI symptoms (***n*** = 94)***p*** value\***Age, mean (SD), years**49.3 (14.5)51.9 (14.9)47.5 (14.0)0.0599**Gender** Male74 (47.1%)24 (38.1%)50 (53.2%)0.0633 Female83 (52.9%)39 (61.9%)44 (46.8%)**Comorbidities** Hypertension28 (17.8%)12 (19.1%)16 (17.0%)0.7451 Diabetes9 (5.7%)5 (7.9%)4 (4.3%)0.5337 Chronic kidney disease3 (1.9%)1 (1.6%)2 (2.1%)1.0000 Chronic lung disease2 (1.3%)1 (1.6%)1 (1.1%)1.0000 Heart disease2 (1.3%)2 (3.2%)00.1595 Malignancy4 (2.6%)1 (1.6%)3 (3.2%)0.9135 Total with ≥ 1 comorbidity55 (35.0%)24 (38.1%)31 (33.0%)0.5101**Symptoms** Fever65 (41.4%)23 (36.5%)42 (44.7%)0.3082 Cough109 (69.4%)47 (74.6%)62 (66.0%)0.2491 Sore throat12 (7.6%)4 (6.4%)8 (8.5%)0.8468 Muscle soreness44 (28.0%)23 (36.5%)21 (22.3%)0.0527 Fatigue73 (46.5%)44 (69.8%)29 (30.9%)\< 0.001**Initial laboratory parameters, median (IQR)** WBCs count, × 10^9^/L4.9 (3.8--6.3)4.9 (3.4--6.0)5.0 (4.0--6.4)0.4838 Lymphocyte count, × 10^9^/L1.0 (0.7--1.4)1.0 (0.7--1.4)1.0 (0.7--1.5)0.4423 C-reactive protein, mg/L13.2 (3.4--32.9)17.8 (7.2--41.1)9.1 (2.9--30.3)0.0561 ALT level, IU/L21.7 (15.4--38.8)23.1 (15.0--43.0)21.7 (16.2--34.3)0.8062 AST level, IU/L26.2 (20.7--34.7)26.0 (20.0--35.0)26.9 (20.8--34.7)0.7189**Severe cases**41 (26.1%)8 (12.7%)33 (35.1%)0.0016**Corticosteroid usage**112 (71.3%)40 (63.5%)72 (76.6%)0.0751**Hospital course, mean (SD), days** Duration onset to treatment5.3 (5.4)5.9 (6.0)4.9 (4.9)0.2580 Clinical recovery time9.8 (4.9)10.7 (4.5)9.1 (5.2)0.0607 Time of virus nucleic acid turn to negative12.4 (6.4)13.0 (6.1)12.0 (6.7)0.3509 Hospitalization duration16.0 (4.9)16.1 (5.1)15.8 (4.7)0.7003*GI* gastrointestinal, *IQR* interquartile range, *SD* standard deviation, *WBC* white blood cell, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase\**P* values indicate differences between patients with GI symptoms and those without. *P* \< 0.05 was defined as statistically significant

There was no significant difference in viral shedding, the time to clinical recovery, or hospitalization duration between patients with and without GI symptoms (Table [1](#Tab1){ref-type="table"}). Among patients with GI symptoms, 63.5% received corticosteroids treatment, which is much lower than patients without GI symptoms group (63.5% vs 76.6%; *p* = 0.0751). Moreover, less patients with GI symptoms developed into severe cases compared with those without GI symptoms (12.7% vs 35.1%; *p =* 0.0016).

In our experience, 4 out of 10 patients with COVID-19 have significant GI symptoms. There was no significant difference in gender, age, and comorbidities between patients with and without GI symptoms. Leukocyte and lymphocyte counts were similar between the two groups. Besides, there was no significant difference in viral shedding, the time to clinical recovery, or hospitalization duration between patients with and without GI symptoms. Nonetheless, less patients with GI symptoms received corticosteroids and developed into severe cases.

This study suggested that GI symptoms in COVID-19 are frequent but are not associated with the severity of diseases or worse outcomes. However, because SARS-CoV-2 can be found in patient feces and the digestive system, we should be cautious with these potential routes for transmission \[[@CR2], [@CR3]\]. This study is limited by the lacked of data of reverse transcriptase polymerase chain reaction on COVID-19 in GI specimens. Our observations indicate that a substantial number of patients present with predominantly GI symptoms, and caution about this atypical presentation is necessary.
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